Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal

التفاصيل البيبلوغرافية
العنوان: Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal
المؤلفون: Adil Maarouf, L. Daelman, Ayman Tourbah, A Maitrot, M.-P. Chaunu, Caroline Papeix
المصدر: Multiple sclerosis (Houndmills, Basingstoke, England). 18(11)
سنة النشر: 2012
مصطلحات موضوعية: Adult, Pediatrics, medicine.medical_specialty, Time Factors, Disease, Antibodies, Monoclonal, Humanized, Severity of Illness Index, Drug Administration Schedule, Natalizumab, Multiple Sclerosis, Relapsing-Remitting, Sphingosine, Brain mri, Medicine, Humans, Immunologic Factors, business.industry, Drug Substitution, Fingolimod Hydrochloride, Multiple sclerosis, medicine.disease, Fingolimod, Magnetic Resonance Imaging, Treatment Outcome, Neurology, Relapsing remitting, Propylene Glycols, Asthenia, Immunology, Disease Progression, Female, Neurology (clinical), Epilepsies, Partial, Epilepsy, Tonic-Clonic, business, medicine.drug
الوصف: We report the case of a woman with multiple sclerosis who developed a severe neurological condition following natalizumab (NZB) withdrawal and soon after fingolimod (FTY) initiation. FTY was started 3.5 months after a two-year NZB treatment. Fifteen days later, she suffered partial repetitive seizures followed by a tonicoclonic seizure. This was associated with attention difficulties and an increased asthenia. Brain MRI follow-up disclosed large demyelinating active lesions in favour of disease reactivation. This case suggests that FTY introduction may occur less than three months after NZB withdrawal.
تدمد: 1477-0970
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b50d8969f5c53e6f3651fd331c17287
https://pubmed.ncbi.nlm.nih.gov/23184503
حقوق: CLOSED
رقم الأكسشن: edsair.doi.dedup.....6b50d8969f5c53e6f3651fd331c17287
قاعدة البيانات: OpenAIRE